Analysts Set Hologic, Inc. (NASDAQ:HOLX) Target Price at $87.50

Hologic, Inc. (NASDAQ:HOLX) has earned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $89.25.

A number of brokerages recently weighed in on HOLX. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday. Leerink Partners reduced their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th.

Institutional Investors Weigh In On Hologic

A number of large investors have recently modified their holdings of HOLX. Price T Rowe Associates Inc. MD increased its holdings in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the period. The Manufacturers Life Insurance Company raised its position in Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after buying an additional 450,190 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Hologic by 4.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock worth $168,666,000 after acquiring an additional 87,176 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 2.1 %

Hologic stock opened at $80.49 on Friday. Hologic has a one year low of $66.93 and a one year high of $84.67. The business’s fifty day moving average is $81.05 and its 200 day moving average is $78.11. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The stock has a market capitalization of $18.70 billion, a PE ratio of 24.17, a price-to-earnings-growth ratio of 3.03 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the firm earned $0.89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, sell-side analysts predict that Hologic will post 4.36 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.